Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Cardiovascular Events iN Diabetes Plus
Sponsor: University of Oxford
Summary
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Key Details
Gender
All
Age Range
55 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20000
Start Date
2023-03-13
Completion Date
2048-08-17
Last Updated
2024-05-08
Healthy Volunteers
No
Conditions
Interventions
Semaglutide Oral Tablet
Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Placebo oral tablet
Placebo oral semaglutide
Locations (1)
Clinical Trial Service Unit and Epidemiological Studies Unit
Oxford, United Kingdom